SIIT, an Italian company manufacturing innovative healthcare products, announced that the planning, execution, and analysis of its new clinical trial in recurrent bacterial vaginosis will be performed by the contract research organization Opera CRO. The tested product will be the medical device Vagitab-T ®. The involved sites will be in Romania. The first patient will be enrolled during the first quarter of 2023 and the results will be presented after one year.
SIIT is a privately owned company with more than 1200 references on the market, 400 employees, and 60 years of experience. Thanks to advanced technologies and sophisticated manufacturing processes, SIIT is a leading company in the development and contract manufacturing of consumer self-healthcare products. Its R&D department employs 10% of the total staff. The company continuously develops new ideas and experiments with new technologies to launch innovative and useful products for consumers.
For more information via e-mail: email@example.com / Tel: +39 02 4843521
About Opera CRO
Opera CRO is a contract research organization with over 25 years of experience in clinical research for drugs, medical devices, and food supplements. Headquartered in Romania and with local offices in Eastern and Western European countries, Opera CRO has successfully supported hundreds of companies to develop new products. Opera is the subsidiary of TIGERMED, the leading CRO in China, and acts as a bridge between its European clients and the Chinese market.